Table 1.
Definitions of Incidence, Progression, Regression and Disappearance of Age-related Macular Degeneration (AMD) in the Los Angeles Latino Eye Study
| Incidence |
Progression | Regression | Disappearance |
|||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | |||
| Age-Related Eye Disease Study (AREDS) 11-step Severity Scale | ||||||
| Early AMD | ≤ Step 3 | Step 4, 5, 6, 7, or 8 | ≥ 2-step increase | |||
|
| ||||||
| Advanced AMD | ≤ Step 8 | Step 9, 10, or 11 | ||||
|
| ||||||
| Wisconsin Age-Related Maculopathy Grading System Definitions | ||||||
| Early AMD | No early or advanced AMD lesions in both eyes | Either (i) any soft indistinct or reticular drusen, or (ii) retinal pigmentary abnormalities with any type of drusen, in either eye | ≥ 2-step increase from Level 1–3, or ≥ 1-step increase from Level 4 | |||
|
| ||||||
| Advanced AMD | No advanced AMD lesions in both eyes | Exudative AMD or geographic atrophy in either eye | ||||
|
| ||||||
| Drusen size | None or questionable | <63 μm | ≥2 additional involved subfields at follow-up without change in drusen size from baseline | ≥2 fewer involved subfields at follow-up without change in drusen size from baseline | None or questionable | |
| <63 μm | ≥63 to μm <125 μm | <63 μm | None or questionable | |||
| <125 μm | ≥125 μm to <250 μm | ≥63 μm to <125 μm | <63 μm | |||
| <250 μm | ≥250 μm | ≥125 μm to <250 μm | <125 μm | |||
| ≥250 μm | ≥250 μm | <250 μm | ||||
|
| ||||||
| Drusen type | None or HI | HD | ≥2 additional involved subfields at follow-up without change in drusen type from baseline | ≥2 fewer involved subfields at follow-up without change in drusen type from baseline | None or HI | |
| None, HI or HD | SD | HD | None or HI | |||
| None, HI, HD, or | SI | SD | None, HI or HD | |||
| SD | ||||||
| SI | SI | None, HI, HD, or | ||||
| SD | ||||||
|
| ||||||
| Increased retinal pigment | No increased retinal pigment in any subfield | Increased retinal pigment in any subfield | Either (i) ≥2 additional involved subfields at follow-up without change in maximum score from baseline, or (ii) increase in the maximum score at follow-up | Either (i) ≥2 fewer involved subfields at follow-up without change in maximum score from baseline, or (ii) decrease in the maximum score at follow-up | Increased retinal pigment in at least 1 subfield | No increased retinal pigment in all subfields |
|
| ||||||
| RPE depigmentation | No RPE depigmentation in any subfield | Definite RPE depigmentation in any subfield | Either (i) ≥2 additional involved subfields at follow-up without change in maximum score from baseline, or (ii) increase in the maximum score at follow-up | Either (i) ≥2 fewer involved subfields at follow-up without change in maximum score from baseline, or (ii) decrease in the maximum score at follow-up | Definite RPE depigmentation in at least 1 subfield | No RPE depigmentation in all subfields |
|
| ||||||
| Geographic atrophy | No geographic atrophy | Definite geographic atrophy | Increase of ≥2 disc areas, or movement of lesion towards the center | Decrease of ≥2 disc areas, or movement of lesion away from the center | Definite geographic atrophy | No geographic atrophy |
|
| ||||||
| Exudative AMD | No exudative AMD | Exudative AMD | Increase of ≥2 disc areas, or movement of lesion towards the center | Decrease of ≥2 disc areas, or movement of lesion away from the center | Exudative AMD | No exudative AMD |
HI=hard indistinct, HD=hard distinct, SD=soft distinct, SI=soft indistinct, RPE=retinal pigment epithelium